Angiogenesis in hematologic malignancies

Annals of Hematology

Volumn 80, Issue 12, 2001, Pages 695-705

  Moehler, T M ^a   Neben, K ^a   Ho, A D ^a   Goldschmidt, H ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Angiogenesis; Leukemia; Lymphoma; Multiple myeloma; Vasculogenesis

Indexed keywords

2,4 DIMETHYL 5 (2 OXO 1H INDOL 3 YLMETHYLENE) 3 PYRROLEPROPIONIC ACID; 4 DEDIMETHYLAMINOSANCYCLINE; AE 941; ALPHA INTERFERON; ANGIOGENESIS INHIBITOR; ANGIOGENIC FACTOR; CALCIUM CHANNEL BLOCKING AGENT; CILENGITIDE; CYCLOPHOSPHAMIDE; ENDOSTATIN; IDARUBICIN; IM 862; INTERLEUKIN 12; MARIMASTAT; REBIMASTAT; SEMAXANIB; SQUALAMINE; THALIDOMIDE; VASCULOTROPIN ANTIBODY;

CANCER GROWTH; CAPILLARY DENSITY; CLINICAL RESEARCH; DISEASE MARKER; DRUG EFFECT; DRUG RESEARCH; ENDOTHELIUM; HEMATOLOGIC DISEASE; HUMAN; LEUKEMIA; LEUKEMOGENESIS; LYMPHOMA; MICROVASCULATURE; MOUSE; MULTIPLE MYELOMA; MYELODYSPLASTIC SYNDROME; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SOLID TUMOR; STEM CELL; TUMOR VASCULARIZATION;

ANGIOGENESIS INHIBITORS; ANIMALS; BONE MARROW CELLS; ENDOTHELIUM, VASCULAR; GROWTH SUBSTANCES; HEMATOLOGIC NEOPLASMS; HUMANS; NEOVASCULARIZATION, PATHOLOGIC; PROGNOSIS; STEM CELLS;

EID: 0035674462     PISSN: 09395555     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00277-001-0398-3     Document Type: Review

References (126)

1. Cellular vascular endothelial growth factor is a predictor of outcome in patients with acute myeloid leukemia
2. Angiogenesis in acute and chronic leukemias and myelodysplastic syndrome
3. Role of vascular endothelial growth factor/vascular permeability factor in the pathogenesis of Kaposi's sarcoma-associated herpes virus-infected primary effusion lymphomas
4. Bcl-2 expression correlates positively with serum basic fibroblast growth factor (bFGF) and negatively with cellular vascular endothelial growth factor (VEGF) in patients with chronic lymphocytic leukemia
5. Release of the angiogenic cytokine vascular endothelial growth factor (VEGF) from platelets: Significance for VEGF measurements and cancer biology
6. Metalloproteinases in multiple myeloma: Production of matrix metalloproteinase-9 (MMP-9), activation of proMMP-2, and induction of MMP-1 by myeloma cells
7. Production of metalloproteinase-7 (matrilysin) by human myeloma cells and its potential involvement in metalloproteinase-2 activation
8. Soluble IL-6R alpha upregulated IL-6, MMP-1 and MMP-2 secretion in bone marrow stromal cells
9. Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: Identification of prognostic factors in a phase 2 study of 169 patients
10. Expression of vascular endothelial growth factor and its receptors in hematopoietic malignancies
11. Induction of vascular endothelial growth factor expression in synovial fibroblasts by prostaglandin E and interleukin-1: A potential mechanism for inflammatory angiogenesis
12. Conditional switching of vascular endothelial growth factor (VEGF) expression in tumors: Induction of endothelial cell shedding and regression of hemangioblastoma-like vessels by VEGF withdrawal
13. Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal
14. Effects of angiogenesis inhibitors on multistage carcinogenesis in mice
15. Angiogenic growth factors and endostatin in non-Hodgkin's lymphoma
16. The anti-angiogenic drug endostatin induces tumor stabilization after chemoor anti-CD20 therapy of a NOD/SCID mouse model of human high-grade non-Hodgkin's lymphoma
17. The thin red line: Angiogenesis in normal and malignant hematopoiesis
18. CD3-induced T-cell activation in the bone marrow of myeloma patients: Major role of CD4+ cells
19. Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance
20. Assessing tumor angiogenesis using macromolecular MR imaging contrast media
21. Pharmacokinetic parameters in CNS Gd-DTPA enhanced MR-imaging
22. Role of integrins in angiogenesis
23. 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels
24. Disruption of angiogenesis by PEX, a non-catalytic metalloproteinase fragment with integrin binding activity
25. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer
26. Angiogenesis in cancer and other diseases
27. Role of HIF-1[alpha] in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis
28. In vitro and in vivo production of vascular endothelial growth factor by chronic lymphocytic leukemia cells
29. Death to a blood vessel, death to a tumor
30. Thalidomide is an inhibitor of angiogenesis
31. Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1
32. Vascular endothelial growth factor and interleukin-6 in paracrine tumor-stromal cell interactions in multiple myeloma
33. Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma
34. Endostatin induces endothelial cell apoptosis
35. Angiogenic factors in multiple myeloma: Higher levels in bone marrow than in peripheral blood
36. Expression of VEGF and its receptor VEFR-2 by human leukemia cells generates an autocrine loop that mediates cell growth and migration
37. Heterogeneity of angiogenesis and blood vessel maturation in human tumors: Implications for antiangiogenic tumor therapies
38. Role of alpha v integrins during angiogenesis
39. Vascular endothelial growth factor, a possible paracrine growth factor in human acute myeloid leukemia
40. Vasculogenic mimicry and tumor angiogenesis
41. Tumor angiogenesis: Therapeutic implications
42. Clinical applications of research on angiogenesis
43. Expression of vascular endothelial growth factor in lymphomas and Castleman disease
44. Markers of tumor angiogenesis: Clinical applications in prognosis and anti-angiogenic therapy
45. Human myeloid and lymphoid malignancies in the NOD/SCID mouse model: Frequency of apoptotic cells in solid tumors, efficiency and speed of engraftment correlate with vascular endothelial growth factor production
46. In vitro differentiation of endothelial cells from AC133-positive progenitor cells
47. Oral idarubicin in patients with late chronic phase chronic myelogenous leukemia or chronic myelomonocytic leukemia
48. Assessment of tumor microcirculation: A new role of dynamic contrast MR imaging
49. Tissue inhibitor of metalloproteinase-1 alters the tumorigenicity of Burkitt's lymphoma via divergent effects on tumor growth and angiogenesis
50. Vascular endothelial growth factor-B and vascular endothelial growth factor-C expression in renal cell carcinomas: Regulation by the von Hippel-Lindau gene and hypoxia
51. Evidence for a leukemia model for maintenance of vascular endothelium by bone marrow derived endothelial cells
52. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis
53. The hallmarks of cancer
54. Less is more, regularly: Metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice
55. Vascular endothelial growth factor-C expression and its relationship to pelvic lymph node status in invasive cervical cancer
56. Vascular endothelial growth factor and angiopoietin-1 stimulate postnatal hematopoiesis by recruitment of vasculogenic and hematopoietic stem cells
57. Angiogenesis of uterine cervical carcinoma: Characterization by pharmacokinetic magnetic resonance parameters and histological microvessel density with correlation to lymphatic involvement
58. Angiogenic activity of cervical carcinoma: Assessment by functional magnetic resonance imaging-based parameters and a histomorphological approach in correlation with disease outcome
59. Evaluation of angiogenesis and perfusion of bone marrow lesions: Role of semiquantitative and quantitative dynamic MRI
60. Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy
61. Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF
62. Tie2 ligands angiopoietin-2 are coexpressed with vascular endothelial cell growth factor in growing human bone
63. Evidence of increased angiogenesis in patients with acute myeloid leukemia
64. Frequent good partial remission from thalidomide including best response ever in patients with advanced refractory and relapsed multiple myeloma
65. Vascular endothelial growth factor C promotes tumor lymphangiogenesis and intralymphatic tumor growth
66. Inhibition of tumor angiogenesis as a strategy to circumvent acquired resistance to anti-cancer therapeutic agents
67. Establishing a link between oncogenes and tumor angiogenesis
68. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumor growth in vivo
69. Increased bone marrow angiogenesis in B-cell leukemia
70. Angiongenesis in acute promyelocytic leukemia: Induction by vascular endothelial growth factor and inhibition by all-trans retinoic acid
71. Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity
72. Interleukin-6 regulation of matrix metalloproteinase (MMP-2 and MMP-9) and tissue inhibitor of metalloproteinase (TIMP-1) expression in malignant non-Hodgkin's lymphomas
73. MMP2 and MMP-9 expression in adult and childhood acute lymphatic leukemia (ALL)
74. Synergy between an antiangiogenic integrin alpha-v antagonist and an antibody-cytokine fusion protein eradicates spontaneous tumor metastases
75. Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis
76. Angiogenesis and angiogenic mediators in haematological malignancies
77. Vascular channel formation by human melanoma cells in vivo and in vitro: Vasculogenic mimicry
78. Combined effects of angiostatin and ionizing radiation in antitumor therapy
79. Vasculogenic mimicry: How convincing, how novel, and how significant
80. Stable remission after administration of the receptor tyrosine kinase inhibitor SU5416 in a patient with refractory acute myeloid leukemia
81. Bone marrow microcirculation analysis in multiple myeloma by contrast-enhanced dynamic magnetic resonance imaging
82. Thalidomide and CED chemotherapy as salvage therapy in poor prognosis multiple myeloma
83. Increased serum levels of vascular endothelial growth factor predict risk of progression in early B-cell chronic lymphocytic leukemia
84. Angiogenesis in newly diagnosed multiple myeloma: Poor prognosis with increased microvessel density in bone marrow biopsies
85. Chemotherapy with DT-PACE for previously treated multiple myeloma
86. Vascular endothelial growth factor (VEGF) directly enhances osteoclastic bone resorption and survival of mature osteoclasts
87. Response to thalidomide in progressive multiple myeloma is not mediated by inhibition of angiogenic cytokine secretion
88. High plasma basic fibroblast growth factor concentration is associated with response to thalidomide in progressive multiple myeloma
89. Matrix metalloproteinases: Biologic activity and clinical implications
90. Angiostatin: A novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma
91. Increased angiogenesis in the bone marrow of patients with acute leukemia
92. SRC deficiency or blockade of SRC activity in mice provides cerebral protection following stroke
93. Spectrum of tumor angiogenesis in the bone marrow of children with acute lymphoblastic leukemia
94. Non small cell lung carcinoma tumor growth without morphological evidence of neoangiogenesis
95. Angiogenesis in myelodysplastic syndromes
96. Angiogenesis in hairy cell leukemia
97. Bone marrow angiogenesis in patients achieving complete response after stem cell transplantation for multiple myeloma
98. Prognostic value of bone marrow angiogenesis in multiple myeloma
99. Mutant ras oncogenes upregulate VEGF/VPF expression: Implications for induction and inhibition of tumor angiogenesis
100. Matrix metalloproteinases and malignant disease: Recent developments
101. Bone marrow angiogenesis and mast cell density increase simultaneously with progression of human multiple myeloma
102. Angiogenesis and mast cell density with tryptase activity increase simultaneously with pathological progression in B-cell non-Hodgkin's lymphomas
103. Mechanisms of angiogenesis
104. Pieces of eight: Bioactive fragments of extracellular proteins as regulators of angiogenesis
105. A high pretreatment serum vascular endothelial growth factor concentration is associated with poor outcome in non-Hodgkin's lymphoma
106. Simultaneous elevation in the serum concentrations of the angiogenic growth factors VEGF and bFGF is an independent predictor of poor prognosis in non-Hodgkin lymphoma: A single-institution study of 200 patients
107. Endotoxin induce and interferon-alpha suppresses vascular endothelial growth factor (VEGF) production in human peripheral blood mononuclear cells
108. Multiple myeloma with deletion of chromosome 13q is characterized by increased bone marrow neovascularization
109. Serum levels of the angiogenic cytokines basic fibroblast growth factor (bFGF), vascular endothelial growth factor (VEGF) and hepatocyte growth factor (HGF) in multiple myeloma
110. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis
111. Antitumor activity of thalidomide in refractory multiple myeloma
112. Halting angiogenesis suppresses carcinoma cell invasion
113. Induction of tumor lymphangiogenesis by VEGF-C promotes breast cancer metastasis
114. Expression of matrix metalloproteinases and tissue inhibitors of metalloproteinases in reactive and neoplastic lymphoid cells
115. Ischemia- and cytokine-induced mobilization of bone marrow-derived endothelial progenitor cells for neovascularization
116. Current status of antiangiogenic factors
117. Antiangiogenesis is produced by nontoxic doses of vinblastine
118. Bone marrow neovascularization, plasma cell angiogenic potential and matrix metalloproteinase-2 secretion parallel progression of human multiple myeloma
119. Angiogenesis extent and macrophage density increase simultaneously with pathological progression in B-cell non-Hodgkin's lymphomas
120. Peripheral blood platelets express VEGF-C and VEGF which are released during platelet activation
121. Tumor angiogenesis and metastasis - Correlation in invasive breast carcinoma
122. Primary myeloma cells growing in SCID-hu mice: A model for studying the biology and treatment of myeloma and its manifestations
123. Vascular-specific growth factors and blood vessel formation
124. Contribution of natural killer cells to inhibition of angiogenesis by interleukin-12
125. Maspin is an angiogenesis inhibitor